{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": -11.174788, "regularMarketPrice": 1.55, "exchange": "NCM", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "messageBoardId": "finmb_36742485", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1349789400000, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": -0.19500005, "regularMarketTime": 1684180766, "regularMarketDayHigh": 1.7496, "regularMarketDayRange": "1.52 - 1.7496", "regularMarketDayLow": 1.52, "regularMarketVolume": 66317, "regularMarketPreviousClose": 1.745, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 11, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 1.74, "averageDailyVolume3Month": 67158, "averageDailyVolume10Day": 46080, "fiftyTwoWeekLowChange": 0.78999996, "fiftyTwoWeekLowChangePercent": 1.0394737, "fiftyTwoWeekRange": "0.76 - 3.4", "fiftyTwoWeekHighChange": -1.8500001, "fiftyTwoWeekHighChangePercent": -0.5441177, "fiftyTwoWeekLow": 0.76, "fiftyTwoWeekHigh": 3.4, "dividendDate": 1538611200, "earningsTimestamp": 1683801000, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.67, "epsForward": -1.57, "epsCurrentYear": -1.63, "priceEpsCurrentYear": -0.9509202, "sharesOutstanding": 16840300, "bookValue": 1.977, "fiftyDayAverage": 1.1844, "fiftyDayAverageChange": 0.3656, "fiftyDayAverageChangePercent": 0.3086795, "twoHundredDayAverage": 1.479, "twoHundredDayAverageChange": 0.07099998, "twoHundredDayAverageChangePercent": 0.048005395, "marketCap": 26102464, "forwardPE": -0.98726106, "priceToBook": 0.7840162, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "displayName": "Regulus Therapeutics", "symbol": "RGLS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph P. Hagan M.B.A.", "age": 53, "title": "Pres, CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 920728, "fmt": "920.73k", "longFmt": "920,728"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Crispina  Calsada CPA", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 500866, "fmt": "500.87k", "longFmt": "500,866"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher Ray Aker J.D.", "age": 61, "title": "Sr. VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 524790, "fmt": "524.79k", "longFmt": "524,790"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel J. Penksa", "age": 36, "title": "Exec. Director of Fin. & Controller", "yearBorn": 1986, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Firuz  Shakoori", "title": "Head of CMC", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Claire Susan Padgett M.S., M.T., Ph.D.", "title": "Sr. VP of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rekha  Garg M.D., M.S.", "title": "Sr. VP of Clinical Devel. & Regulatory", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}